Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,809,273

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.68 -0.01 (-0.01%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Company News for Aug 3, 2020

Companies In The News Are: MRK, CVX, NOK, CHD.

Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

Merck (MRK) Beats on Q2 Earnings, Misses Sales, Ups View

Merck (MRK) increases earnings and sales guidance for the year, which pushes shares up in pre-market trading.

Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales

Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.

Mark Vickery headshot

More Earnings, Data Following Big Tech Q2 Blowout: XOM, MRK, CAT & More

Markets finish out a busy week in the heart of Q2 earnings season with plenty of other leaders across a spectrum of industries, plus a few new economic reports.

Earnings & Economic Data Deluge

Earnings & Economic Data Deluge

Merck (MRK) Q2 Earnings Beat Estimates

Merck (MRK) delivered earnings and revenue surprises of 20.18% and -0.42%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Increase Y/Y

AstraZeneca (AZN) comes up with better-than expected Q2 results. It maintains its financial outlook for the year. Stock up.

How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised)

Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's(MRK) performance when it reports second-quarter earnings.

Pfizer (PFE) Q2 Earnings Top, Sales Hurt by Coronavirus, View Up

Pfizer (PFE) beats estimates for earnings while missing the same for sales. It slightly raises its financial outlook for the year.

How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?

Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q2 Earnings?

The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.

Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of new drug sales. However, the impact of coronavirus pandemic remains to be seen.

Benjamin Rains headshot

3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth

Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...

Will Pfizer's (PFE) BioPharma Unit Drive Its Q2 Earnings?

In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the second quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.

Exelixis Starts Study on Cabometyx Combo in Kidney Cancer

Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Merck (MRK) closed at $79.41, marking a -0.58% move from the previous day.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation

Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.

Merck's NDA for Heart Failure Candidate Gets Priority Review

FDA decision on Merck (MRK) and its Germany-based partner Bayer's vericiguat as a treatment to reduce heart failure is expected in January 2021.

AstraZeneca's Farxiga Gets Fast Track Tag for New Indication

AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.

Kinjel Shah headshot

Pharma Stock Roundup: J&J Q2 Earnings, FDA Approvals, Fast Track Tags & More

J&J (JNJ) beats Q2 estimates for earnings and sales. FDA grants fast track designation to Pfizer's (PFE) coronavirus vaccine candidates.

Daniel Laboe headshot

What To Expect From The Crazy Earnings Season Ahead

Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?

Nabriva Soars on Agreement With Merck to Distribute Sivextro

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance

J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.